Allogene therapeutics inc ALLO.US 總覽分析

美股醫療保健
(ALLO 無簡報檔)

ALLO 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面評分中等,已經有部位可以持續持有,若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上

ALLO 近期報酬表現

0.86%

Allogene therapeutics inc

4.57%

同產業平均

3.26%

S&P500

與 ALLO 同產業的標的表現

  • NTLA Intellia therapeutics inc
    價值 4 分趨勢 3 分波段 5 分籌碼 3 分股利 1 分
    查看更多

ALLO 公司資訊

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

ALLO 股價